Dr. Mattis F. Ranthe will take over the responsibility for the Company's development pipeline activities from Dr. Lars J. Petersen, who will step down from his position as part-time Medical Director, Oncology, in light of the new CMO role. At ExpreS[2]ion, the Company's medical activities will continue to be supported by drug development consultants within oncology, which will now be under Mattis' leadership.

Furthermore, considering ExpreS[2]ion's increased strategic focus on research and development and clinical planning/management, Mr. Eske Rygaard-Hjalsted is resigning from the position as Vice President, Business Development.

These organizational changes are made to facilitate the further advancement of the Company's pipeline development projects, with clinical trials planned within the next 1-2 years for COVID-19, breast cancer, influenza and malaria.

ExpreS[2]ion's CEO Bent Frandsen comments: 
"It is with great pleasure that I welcome Mattis to the ExpreS[2]ion team as our new CMO. I feel confident that his skillset and experience will ensure a further professionalisation of our development pipeline's clinical activities."

Short biography of the new amendment to the management team

Dr. Mattis Flyvholm Ranthe, Chief Medical Officer

Dr. Mattis F. Ranthe holds a PhD in Cardiovascular Epidemiology (2013), and a Medical Diploma (MD) (2006) from the University of Copenhagen, Denmark. Mattis' background as a physician with a broad clinical experience, research in academia, positions in various pharmaceutical companies (including Novo Nordisk, ALK, and GSK Vaccines), and extensive taught courses in drug development makes him perfectly suited to design and lead successful clinical development programs for ExpreS[2]ion.

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Telefon: +46 11 32 30 732

E-post: ca@skmg.se
 

This press release constitutes inside information that ExpreS2ion Biotech Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was sent for publication, through the agency of the contact persons set out above, at the time stated by the Company's news distributor, Cision, at the publication of this press release.